Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  European Journal of Cancer

• Publication date

  2002-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0959-8049(02)00035-7PMID 12008197
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of Multidrug-Resistance Convertors: Sense or Nonsense?

  2000cited by this paper
• Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

  2000cited by this paper
• The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

  2000cited by this paper
• Efflux of Rhodamine From CD56+ Cells as a Surrogate Marker for Reversal of P-Glycoprotein–Mediated Drug Efflux by PSC 833

  1999cited by this paper
• A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (PgP) given alone and in combination with Taxol in patients with solid tumors

  1999cited by this paper
• Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833.

  1999cited by this paper
• Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein

  1999cited by this paper
• Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

  1998cited by this paper
• Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.

  1997cited by this paper
• Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

  1997cited by this paper
• Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.

  1997cited by this paper
• Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay

  1996cited by this paper
• Serum can inhibit reversal of multidrug resistance by chemosensitisers.

  1996cited by this paper
• Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?

  1996cited by this paper
• Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.

  1996cited by this paper
• Docetaxel (Taxotere): an overview of first-line monotherapy.

  1995cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• Decreased potency of MDR‐modulators under serum conditions determined by a functional assay

  1995cited by this paper
• Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation.

  1995cited by this paper
• P-glycoprotein in adult solid tumors. Expression and prognostic significance.

  1995cited by this paper
• Taxol metabolism and disposition in cancer patients.

  1995cited by this paper
• Clinical trials of agents that reverse multidrug resistance. A literature review

  1993cited by this paper
• Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

  1993cited by this paper
• Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo.

  1992cited by this paper
• Reversal of multidrug resistance.

  1990cited by this paper
• Clinical trials of agents that reverse multidrug-resistance.

  1989cited by this paper

• Research Progress on the Mechanisms of Action, Pharmacological Activities and Clinical Application of P-glycoprotein Inhibitors.

  2026cites this paper
• Design and Synthesis of Cyclolipopeptide Mimics of Dysoxylactam A and Evaluation of the Reversing Potencies against P-Glycoprotein-Mediated Multidrug Resistance.

  2024cites this paper
• Simplified Derivatives of Tetrandrine as Potent and Specific P-gp Inhibitors to Reverse Multidrug Resistance in Cancer Chemotherapy.

  2023cites this paper
• Extended-ensemble docking to probe dynamic variation of ligand binding sites during large-scale structural changes of proteins

  2022cites this paper
• Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.

  2021cites this paper
• ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients

  2021cites this paper
• Extended-Ensemble Docking to Probe Evolution of Ligand Binding Sites During Large-Scale Structural Changes of Proteins

  2021cites this paper
• Cancer Stem Cells as a Potential Target to Overcome Multidrug Resistance

  2020cites this paper
• Novel benzopyran derivatives and their therapeutic applications: a patent review (2009–2016)

  2017cites this paper
• Rôle du récepteur des xénobiotiques PXR (Pregnane X Receptor) et de ses gènes cibles sur la sensibilité des lignées de cancer de prostate aux inhibiteurs de kinases

  2017cites this paper
• Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer

  2016cites this paper
• Treatment regimens of classical and newer taxanes

  2016cites this paper
• Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.

  2015cites this paper
• Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies.

  2015cites this paper
• Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

  2015cites this paper
• Metabolism of the taxanes including nab-paclitaxel

  2015cites this paper
• The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target

  2015cites this paper
• The reversal of antineoplastic drug resistance in cancer cells by β-elemene

  2015cites this paper
• A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation.

  2015cites this paper
• PET Imaging of ABC Transporters in the BBB

  2014cites this paper
• Physiological modulation approaches to improve cancer chemotherapy : a review.

  2014cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2014cites this paper
• β-Elemene, a compound derived from Rhizoma zedoariae, reverses multidrug resistance mediated by the ABCB1 transporter.

  2014cites this paper
• ABCB1 single nucleotide polymorphisms (1236C>T, 2677G>T, and 3435C>T) do not affect transport activity of human P-glycoprotein

  2013cites this paper
• The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.

  2013cites this paper
• The Effect of St John’s Wort on the Pharmacokinetics of Docetaxel

  2013cites this paper
• Molecular Docking Characterizes Substrate-Binding Sites and Efflux Modulation Mechanisms within P-Glycoprotein

  2013cites this paper
• A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry

  2013cites this paper
• Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes.

  2012cites this paper
• Three decades of P-gp inhibitors: skimming through several generations and scaffolds.

  2012cites this paper
• The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier.

  2012cites this paper
• Reversal of P-gp and MRP1-mediated multidrug resistance by H6, a gypenoside aglycon from Gynostemma pentaphyllum, in vincristine-resistant human oral cancer (KB/VCR) cells.

  2012cites this paper
• IMPROVING DELIVERY OF ELACRIDAR TO ENHANCE EFFICACY OF MOLECULARLY-TARGETED AGENTS IN TREATMENT OF GLIOBLASTOMA

  2012cites this paper
• Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.

  2012cites this paper
• Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

  2011cites this paper
• Pathways of chemotherapy resistance in castration-resistant prostate cancer.

  2011influential citation
• Endocrine-Related Cancer ( 2011 ) 18 R 103 – R 123 Pathways of chemotherapy resistance in castration-resistant prostate cancer

  2011influential citation
• Immunosuppressors as multidrug resistance reversal agents.

  2010cites this paper
• Targeted chemotherapy in drug-resistant tumors, noninvasive imaging of P-glycoprotein-mediated functional transport in cancer, and emerging role of Pgp in neurodegenerative diseases.

  2010cites this paper
• Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells.

  2010cites this paper
• Multi‐Drug‐Resistance‐Reverting Agents: 2‐Aryloxazole and 2‐Arylthiazole Derivatives as Potent BCRP or MRP1 Inhibitors

  2009cites this paper
• Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs.

  2009cites this paper
• Is there a place for drug combination strategies using clinical pharmacology attributes?--review of current trends in research.

  2009cites this paper
• Reversal Agents for P‐Glycoprotein‐Mediated Multidrug Resistance

  2009cites this paper
• Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.

  2009cites this paper
• Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.

  2009cites this paper
• Pharmacogenetics of membrane transporters: a review of current approaches.

  2008cites this paper
• Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

  2008cites this paper
• Expression and activity of taxane-metabolizing enzymes in ovarian tumors.

  2008cites this paper
• P-Glycoprotein Expression and Function in the Retinal Pigment Epithelium

  2008cites this paper
• Influence of ketoconazole on the fecal and urinary disposition of docetaxel

  2007cites this paper
• Chemotherapy dosing part I: scientific basis for current practice and use of body surface area.

  2007cites this paper
• Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel

  2006cites this paper
• The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

  2006cites this paper
• Clinical Pharmacokinetics of Docetaxel

  2006cites this paper
• In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies.

  2006cites this paper
• Pharmacokinetic Optimization of Docetaxel Dosing

  2006cites this paper
• Nachweis und Modulation der P-Glykoprotein-vermittelten Multidrugresistenz bei akuter myeloischer Leukämie in vitro

  2005cites this paper
• Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells.

  2005cites this paper
• Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

  2005cites this paper
• ABC Transporter Proteins and Cellular Drug Resistance

  2004cites this paper
• The ABC Transporters MDR1 and MRP2: Multiple Functions in Disposition of Xenobiotics and Drug Resistance

  2004cites this paper
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

  2004cites this paper
• Reversal of MDR by Verapamil Analogues

  2004cites this paper
• Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance

  2004cites this paper
• Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002

  2003cites this paper
• Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.

  2003cites this paper
• Overview of the clinical efficacy of investigational anticancer drugs

  2003cites this paper
• P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement.

  2003cites this paper
• Structure–activity relationship: analyses of p‐glycoprotein substrates and inhibitors

  2003cites this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cites this paper
• P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance.

  2002cites this paper